Ceepackaging

Products

Valois Pharma to unveil inhaler

The market perspective

Asthma and Chronic Obstructive Pulmonary Disease (COPD) are very common diseases which represent a huge worldwide market estimated at $20b in drug sales in 2006 and expected to continue to grow sharply to reach $35b in 2011.

Drug delivered via DPIs represent the fastest growing segment with an estimated of 175 million DPI units manufactured globally in 2006. One of the main drivers of success is the patient preference for DPIs because they do not require breath co-ordination as opposed to pressurized Metered Dose Inhalers (pMDIs). A further benefit of DPIs versus pMDIs is they are propellant-free which makes them an attractive alternative because they are environmentally-friendly.

Prohaler™ Technology

Prohaler™ has been developed with a patient-based design approach which makes it highly intuitive & simple to use by all patients. The use of Prohaler™ requires only 3 simple steps: Open, Breath-in and Close. A dose counter reminds the patient of the number of doses left in the device. Prohaler™ also incorporates visual and audible feed-back systems to facilitate ease-of-use and patient control.

Prohaler™ features a novel powder dispersion technology enabling high lung deposition even whilst operating at low patient’s inhalation flow rate.

Prohaler™ incorporates a unique patient safety feature to avoid any risk of double-dosing and wasted doses.

Moreover, the drug product is protected inside individual blisters which are only opened upon inhalation by the patient, hence providing optimal powder protection.

Prohaler™ is protected by more than 35 patent and patent application families.